Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/122089
Targeting cannabinoid CB2 receptors in the Central Nervous System. Medicinal chemistry approaches and focus on neurodegenerative disorders affecting movement
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Endocannabinoids activate two types of specific G-protein-coupled receptors (GPCRs), namely cannabinoid CB1 and CB2. Contrary to the psychotropic actions of agonists of CB1 receptors, and serious side effects of the selective antagonists of this receptor, drugs acting on CB2 receptors appear as promising drugs to combat CNS diseases (Parkinson's disease, Huntington's chorea, cerebellar ataxia, amyotrohic lateral sclerosis). Differential localization of CB2 receptors in neural cell types and upregulation in neuroinflammation are keys to understand the therapeutic potential in inter alia diseases that imply progressive neurodegeneration. Medicinal chemistry approaches are now engaged to develop imaging tools to map receptors in the living human brain, to develop more efficacious agonists, and to investigate the possibility to develop allosteric modulators.
Matèries (anglès)
Citació
Citació
NAVARRO BRUGAL, Gemma, MORALES, Paula, RODRÍGUEZ CUETO, Carmen, FERNÁNDEZ-RUIZ, Javier, JAGEROVIC, Nadine, FRANCO FERNÁNDEZ, Rafael. Targeting cannabinoid CB2 receptors in the Central Nervous System. Medicinal chemistry approaches and focus on neurodegenerative disorders affecting movement. _Frontiers in Neuroscience_. 2016. Vol. 10. [consulta: 15 de gener de 2026]. ISSN: 1662-4548. [Disponible a: https://hdl.handle.net/2445/122089]